Core Viewpoint - Xiaopeng Motors (09868) has launched four new models and established a timeline for AI product deployment, indicating a strong growth trajectory supported by technological advancements and international expansion [1] Group 1: Product Development - The second-generation visual intelligent driving system (VLA 2.0) is expected to achieve mass production in the first quarter of this year [1] - Robotaxi operations are set to commence this year, showcasing the company's commitment to autonomous driving technology [1] - Human-shaped robots and flying cars are anticipated to reach mass production in the second half of this year, further diversifying the product lineup [1] Group 2: Growth Potential - The company is expected to maintain a high growth trend due to new vehicle iterations, the large-scale production of the dual-energy platform, and the widespread adoption of intelligent driving features [1] - Continuous investment in AI chips and autonomous driving technology is projected to provide long-term growth momentum for the company [1] Group 3: International Expansion - The company is accelerating its overseas expansion efforts, which may enhance its market presence and revenue streams [1]

截至本周，已有25地发布2025年版医保及商保目录执行文件、22地明确召开药事会时间。该行建议持续 关注医保新纳入品种/适应症后续销售放量情况，以及商保的实际执行及支付情况。新年伊始，港股医 药板块表现亮眼，下周JPM行业大会召开在即，有望进一步催化板块行情。 该行认为，2026年板块稳中向好态势延续，后续选股逻辑或将重回基本面和估值，关注存在基本面预期 差、当前仍被低估、安全边际较大的头部个股。 智通财经APP获悉，交银国际发布研报称，2025年10月至今，内资通过港股通持有医药股的比例在小幅 下降后逐渐企稳，外资持仓整体平稳，内外资加大创新药布局的大方向不变。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 交銀國際控股有限公司 | | | 呈交日期: | 2026年1月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03329 | 說明 | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,734,392,000 | | 0 | | 2,734,392,000 | | 增加 / 減少 (-) | | ...

Core Viewpoint - The report from CMB International indicates that the mainland market is entering a phase of policy validation and profit recovery as the "14th Five-Year Plan" begins. The evolution of pricing power structure is attracting long-term capital back to new core assets [1] Group 1: Key Variables for January - Three major variables to focus on in January include: 1) the first batch of major projects and revenue-increasing policy details under the "14th Five-Year Plan" [1] 2) overseas liquidity [1] 3) consumer data and seasonal liquidity before the Spring Festival holiday [1] Group 2: Investment Strategy - The company suggests focusing on "domestic demand reconstruction" and "resilience in overseas markets," balancing offensive and defensive strategies [1] - Selected stocks for January include: 1) Prosperity Industrial Trust (00778) [1] 2) NVIDIA (NVDA.US) [1] 3) Hesai Technology (02525) [1] 4) Sangfor Technologies (01530) [1] 5) Yili Group (600887.SH) [1] 6) GCL-Poly Energy (03800) [1]

交银国际(03329)发布公告，谭岳衡先生因工作调整原因辞任公司执行董事，自2026年1月1日起生效。 于其辞任后，谭先生将自动终止担任董事会战略及风险管理委员会委员。 ...

智通财经APP讯，交银国际(03329)发布公告，谭岳衡先生因工作调整原因辞任公司执行董事，自2026年 1月1日起生效。于其辞任后，谭先生将自动终止担任董事会战略及风险管理委员会委员。 ...

非執行董事 肖霆先生 （董事長） 朱忱女士 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED 交銀國際控股有限公司 （於香港註冊成立的有限公司） （股份代號：3329） 董事名單及其角色與職能 交銀國際控股有限公司董事會成員載列如下，自2026年1月1日起生效： 相關董事會附屬委員會成員載列如下： | 董事 | 戰略及風險 管理委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 肖霆先生 | C | | | | | 朱忱女士 | M | | M | M | | 謝潔先生 | M | | | | | 王賢家先生 | M | | | | | 馬宁先生 | | M | M | C | | 林志軍先生 | | C | M | M | | 浦永灝先生 | | M | C | M | 附註： C 委員會主席 M 委員會成員 香港，2025年12月31日 執行董事 謝潔先生 （首席執行官） 王賢家先生 （副行政總裁、首席風險官） 獨立非執行董事 馬宁先生 林志軍先生 浦永灝先生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED 交銀國際控股有限公司 執行董事辭任 交銀國際控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）宣佈，譚岳衡先生 （「譚先生」）因工作調整原因辭任本公司執行董事，自2026年1月1日起生效。於其辭任 後，譚先生將自動終止擔任董事會戰略及風險管理委員會委員。 譚先生已確認，彼與董事會並無意見分歧，亦無有關其辭任的事宜須提請本公司股東垂 注。 董事會謹藉此機會對譚先生於其任期內對本公司作出的寶貴貢獻致以衷心感謝。 承董事會命 交銀國際控股有限公司 公司秘書 曾佳荔 香港，2025年12月31日 （於香港註冊成立的有限公司） （股份代號：3329） 於本公告日期，董事會包括非執行董事肖霆先生及朱忱女士；執行董事謝潔先生、 王賢家先生及譚岳衡先生；及獨立非執行董事馬宁先生、林志軍先生及浦永灝先生。 ...

Group 1 - The core viewpoint of the report is that there is a trend of increasing domestic innovative drug transactions as the year-end approaches, with a positive outlook for value recovery by 2026 [1] - Since October, the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect has slightly decreased, while foreign investment remains stable, indicating a continued focus on innovative drug layouts by both domestic and foreign investors [1] - This week, multiple business development (BD) transactions exceeding $1 billion have been completed, involving both multinational corporations (MNCs) and small to medium-sized biotech companies, suggesting a concentration of new BD opportunities as the year ends [1] Group 2 - The report recommends focusing on specific segments: 1) Innovative drugs such as 3SBio (01530), Eucure Biopharma (06996), and BeiGene (06160), which have rich catalysts and valuations that do not yet reflect the core value of major products; 2) CXO companies like WuXi AppTec (02269) that benefit from high downstream demand and marginal recovery in financing; 3) Hospital, medical device, and diagnostics sectors that may have reversal opportunities as regulatory uncertainties gradually ease [2]

Core Viewpoint - The company, Jiao Yin International (03329), held a special shareholders' meeting on December 17, 2025, where three ordinary resolutions were approved, including the renewal of property leasing agreements and new financial service frameworks until December 31, 2028 [1] Group 1: Shareholder Meeting Outcomes - The special shareholders' meeting resulted in the approval of three ordinary resolutions with a voting outcome of 99.999314% in favor, representing 145,785,167 shares, while only 0.000686% opposed, equating to 1,000 shares [1] - The resolutions included the approval, ratification, and confirmation of an automatic renewal property leasing framework agreement for three years until December 31, 2028, along with the approval of new financial service and fintech service framework agreements for the same period [1] - The voting was conducted by Hong Kong Central Securities Depository Limited, and due to related party transactions, the controlling shareholder, Bank of Communications, which holds approximately 73.14% of the company, abstained from voting [1] Group 2: Stock Performance - As of the close on December 18, 2025, Jiao Yin International's stock price was 0.36 HKD, reflecting a decrease of 1.37% from the previous trading day, with a trading volume of 458,200 HKD [1] - The stock has experienced a 52-week high of 1.08 HKD and a low of 0.25 HKD, indicating significant volatility in its market performance [1]